Incyte (INCY) Operating Income Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.97% |
| Dec 31, 2025 | 15.38% |
| Sep 30, 2025 | 142.16% |
| Jun 30, 2025 | 18.11% |
| Mar 31, 2025 | 18.22% |
| Dec 31, 2024 | 25.98% |
| Sep 30, 2024 | 1.69% |
| Jun 30, 2024 | -46.93% |
| Mar 31, 2024 | 4.41% |
| Dec 31, 2023 | 58.91% |
| Sep 30, 2023 | 47.15% |
| Jun 30, 2023 | 18.41% |
| Mar 31, 2023 | 18.83% |
| Dec 31, 2022 | 111.23% |
| Sep 30, 2022 | 55.91% |
| Jun 30, 2022 | 103.68% |
| Mar 31, 2022 | 23.51% |
| Dec 31, 2021 | 29.87% |
| Sep 30, 2021 | 60.23% |
| Jun 30, 2021 | 25.86% |
| Mar 31, 2021 | 22.35% |
| Dec 31, 2020 | 57.27% |
| Sep 30, 2020 | 122.66% |
| Jun 30, 2020 | 101.49% |
| Mar 31, 2020 | -149.01% |
| Dec 31, 2019 | 41.68% |
| Sep 30, 2019 | 13.94% |
| Jun 30, 2019 | 41.96% |
| Mar 31, 2019 | 39.22% |
| Dec 31, 2018 | 4.53% |
| Sep 30, 2018 | 34.25% |
| Jun 30, 2018 | 36.89% |
| Mar 31, 2018 | -74.93% |
| Dec 31, 2017 | -34.34% |
| Sep 30, 2017 | 28.34% |
| Jun 30, 2017 | -13.76% |
| Mar 31, 2017 | -31.27% |
| Dec 31, 2016 | -8.16% |
| Sep 30, 2016 | 20.39% |
| Jun 30, 2016 | 25.27% |
| Mar 31, 2016 | 33.73% |
| Dec 31, 2015 | -0.05% |
| Sep 30, 2015 | 65.95% |
| Jun 30, 2015 | -20.52% |
| Mar 31, 2015 | 18.95% |